about
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015Novel insights into the mechanism of action of lenalidomide.NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapyThe presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohortNKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.eIF2α phosphorylation as a biomarker of immunogenic cell death.Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells.Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.Gene Therapy in a Patient with Sickle Cell Disease.A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin.Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.Natural killer cell mediated immunosurveillance of pediatric neuroblastomaThe ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.Trial Watch: Lenalidomide-based immunochemotherapy.Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
P50
Q28553228-6FD721E6-4E6B-4F49-BD7D-4EE819476495Q34373253-2F9B5209-163E-43C9-B400-D5E8B833A87CQ34541173-FB07B006-ECCB-4596-95B3-0D2B579561A0Q36356176-19F97C43-C74D-41CB-98D4-47DEB8226C82Q36862687-03492386-10E0-41A0-A131-DB89982320BEQ36866176-3D284363-D70B-44DF-928A-E5C69B15BE27Q37616478-5C893C4C-C63C-4163-9A39-A8D53B6719FBQ37616484-DA957E19-9E56-4A3B-B84A-7A54758A7D18Q38369971-8A0151E9-07C3-494D-9B2E-797FC3BE9797Q38823705-FA79E94B-9D70-4E54-B03B-9A4E21BE248AQ38886708-9BB84D9B-FAE7-4CBC-A922-42121E96C23BQ39280008-EF60EFCC-BAD0-4CA2-8F16-69BEC5498EC2Q39546314-E6E02CDC-89EE-407E-8B0A-E235B8E2360CQ39865674-0977307C-1485-490D-9204-79E81F192446Q40313066-9FC6F1EE-3222-4E9B-AEE6-23BBB10CAA00Q40373656-33ACF3FE-5CB5-4764-A544-0314526E4435Q40939669-C86584FF-C594-437E-9257-8A5773B9B3D9Q41578364-06476F73-0CCA-4BE9-9BA7-236ADD521F12Q41625138-A9AFB5FE-DB5D-4559-BB2F-27851EFA3E8EQ42737828-6C7128CF-49EA-4A84-B51E-E6144A2266BFQ43733739-D2DE02D2-13E6-4992-BD8F-C799E3553B2D
P50
description
onderzoeker
@nl
name
Michaela Semeraro
@ast
Michaela Semeraro
@en
Michaela Semeraro
@es
Michaela Semeraro
@fr
Michaela Semeraro
@sl
type
label
Michaela Semeraro
@ast
Michaela Semeraro
@en
Michaela Semeraro
@es
Michaela Semeraro
@fr
Michaela Semeraro
@sl
prefLabel
Michaela Semeraro
@ast
Michaela Semeraro
@en
Michaela Semeraro
@es
Michaela Semeraro
@fr
Michaela Semeraro
@sl
P214
P269
P106
P1412
P21
P214
P269
P2798
P31
P569
1974-09-11T00:00:00Z
P6634
michaela-semeraro-7a97435
P735
P7859
viaf-311838754